Emyria Ltd (ASX:EMD) has expanded its clinical service subsidiary, Emerald Clinics, with the addition of a second site in Melbourne off the back of record patient appointments in January 2021.
The new East Melbourne site is co-located with Victorian Counseling and Psychological Services (VCPS) - a major provider of mental health services across Melbourne.
VCPS houses clinical psychologists, counsellors and psychiatrists.
Registration trials
This will boost Emyria’s access to mental health services ahead of registration trials for drug program EMD-003 - targeting unmet needs in mental health.
To further support the registration of EMD-003, Emyria has also partnered with a well-established regulatory affairs consultancy with prior experience and success in schedule-3 registrations.
The VCPS location is also being evaluated as a potential site for psychedelic-assisted therapy trials which are being developed in partnership with Mind Medicine Australia.
Shares are up more than 7% to 15 cents, approaching the record high of 16 cents set last month.
Unique collaboration opportunities
Managing director Dr Michael Winlo said: “The new site is unique in that it is co-located with Victorian Counseling and Psychological Services and offers unique collaboration opportunities with mental health clinicians including psychologists and psychiatrists.
“We anticipate that these collaborations will assist our pivotal drug registration clinical trials for EMD-003 - a cannabinoid medicine targeting unmet needs in mental health - as well as support the development of evidence-based clinical protocols and therapy standards for psychedelic-assisted therapy trials.
“Such trials are currently in development with partner Mind Medicine Australia to help improve our understanding of the role these treatments might play in treating serious mental health concerns like PTSD and major depression.”
With the addition of the second site in Melbourne, Emerald Clinics will be operating its evidence-generating care model from six locations around Australia.
Each Emerald Clinics site gathers high-quality clinical data with consenting patients using a bespoke data platform.
To date, Emyria has used this platform to gather detailed product, safety and efficacy data with more than 3,000 patients prescribed pharmaceutical-grade cannabinoids.
The Emyria data asset is one of the largest clinical-trial grade data sets in the world and helps improve care for Emerald Clinic’s patients as well as provide a source of unique IP and drug development insights.
The second Melbourne Emerald Clinics location is at 62 Wellington Parade, East Melbourne, and opens on February 15, 2021.